Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dextromethorphan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2A known ✓ | Q12879 | 7/20 | 0.95 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 6/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.95 |
| ▸ | GRIN2D | O15399 | 6/20 | 0.95 |
| ▸ | GRIN3B | O60391 | 6/20 | 0.95 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.95 |
| ▸ | GRIN2C | Q14957 | 6/20 | 0.95 |
| ▸ | GRIN3A | Q8TCU5 | 6/20 | 0.95 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.95 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.95 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.95 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.95 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.95 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.95 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.95 |
| ▸ | TSHR | P16473 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levomethorphan SCHEMBL4910539 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL29359586 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Racemethorphan SCHEMBL4894005 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL121923 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL4532860 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Racemethorphan SCHEMBL30052214 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL4882307 | 0.99 | CYP2D6 (0.98) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL121924 | 0.99 | CYP3A4 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL3325972 | 0.99 | GRIN1 (0.98) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Racemethorphan SCHEMBL6855351 | 0.99 | CYP3A4 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107265-A1 | PHARMACEUTICAL DOSAGE FORMS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | ANTECIP BIOVENTURES II LLC (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2025009819-A1 | CUTTABLE AND CONSUMABLE TAPE-TYPE OR BAR-TYPE PREPARATION ENABLING DRUG DOSE CONTROL THROUGH LENGTH | 충북대학교 산학협력단 | 2025-01-09 | — | — | WO | claimed |
| US-20230372326-A1 | Pain Medicine Combination and Uses Thereof | Mindlab LLC | 2023-11-23 | — | — | US | claimed |
| CN-115300511-A | Medical application of composition | 杭州剂泰医药科技有限责任公司 | 2022-11-08 | — | — | CN | claimed |
| CN-115245515-A | Medical application of composition | 杭州剂泰医药科技有限责任公司 | 2022-10-28 | — | — | CN | claimed |
| US-11413440-B2 | Three-dimensional microfluidics devices for the delivery of actives | JOHNSON & JOHNSON CONSUMER INC. (US) | 2022-08-16 | — | — | US | claimed |
| CN-113209042-A | Dextromethorphan hydrobromide quinidine sulfate capsule and preparation method thereof | 珠海润都制药股份有限公司 | 2021-08-06 | — | — | CN | claimed |
| US-11033572-B2 | Molecular adjuvants for enhanced cytosolic delivery of active agents | UNIVERSITEIT GENT (BE) | 2021-06-15 | — | — | US | claimed |
| EP-3813809-A1 | THREE-DIMENSIONAL MICROFLUIDICS DEVICES FOR THE DELIVERY OF ACTIVES | Johnson & Johnson Consumer Inc. (US) | 2021-05-05 | — | — | EP | claimed |
| CN-112312898-A | Three-dimensional microfluidic device for delivery of active substances | 强生消费者公司 | 2021-02-02 | — | — | CN | claimed |
| US-20190125734-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | NANOEGG RESEARCH LABORATORIES, INC. (JP) | 2019-05-02 | — | — | US | claimed |
| US-20190111049-A1 | Pain Medicine Combination and Uses Thereof | Mindlab, LLC | 2019-04-18 | — | — | US | claimed |
| EP-3456353-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | Nanoegg Research Laboratories, Inc. (JP) | 2019-03-20 | — | — | EP | claimed |
| CN-105491885-B | Pain medication combination and application thereof | 思想实验室有限责任公司 | 2018-09-25 | — | — | CN | claimed |
| CN-105491885-A | Pain medicine combination and uses thereof | Mindlab LLC | 2016-04-13 | — | — | CN | claimed |
| US-20160030417-A1 | Pain Medicine Combination and Uses Thereof | Mindlab LLC | 2016-02-04 | — | — | US | claimed |
| EP-2964022-A1 | PAIN MEDICINE COMBINATION AND USES THEREOF | Mindlab LLC (US) | 2016-01-13 | — | — | EP | claimed |
| WO-2014138669-A1 | PAIN MEDICINE COMBINATION AND USES THEREOF | Mindlab LLC (US) | 2014-09-12 | — | — | WO | claimed |
| US-20080070939-A1 | LOCAL ANESTHETIC COMPOSITIONS CONTAINING DEXTROROTATORY MORPHINAN DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CHI MEI FOUNDATION HOSPITAL (TW) | 2008-03-20 | — | — | US | claimed |
| US-5932589-A | ORAL DRUG | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 1999-08-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125734-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | CHRM3, ACHE, CHRNB1 | GRIN2A 1379/4885SIGMAR1 3585/4885CYP2D6 2313/4885 |
| US-20080070939-A1 | LOCAL ANESTHETIC COMPOSITIONS CONTAINING DEXTROROTATORY MORPHINAN DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | OPRM1, OPRD1, CYP2D6 | GRIN2A 185/4885SIGMAR1 248/4885CYP2D6 3/4885 |
| US-11033572-B2 | Molecular adjuvants for enhanced cytosolic delivery of active agents | TLR9, PLA2G4C, STING1 | GRIN2A 2758/4885SIGMAR1 1389/4885CYP2D6 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.